Cibc World Market Inc. Sells 6,929 Shares of CVS Health Corporation $CVS

Cibc World Market Inc. lessened its holdings in shares of CVS Health Corporation (NYSE:CVS) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 523,735 shares of the pharmacy operator’s stock after selling 6,929 shares during the quarter. Cibc World Market Inc.’s holdings in CVS Health were worth $41,564,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Sivia Capital Partners LLC lifted its holdings in shares of CVS Health by 19.7% in the fourth quarter. Sivia Capital Partners LLC now owns 3,769 shares of the pharmacy operator’s stock valued at $299,000 after purchasing an additional 621 shares in the last quarter. Lido Advisors LLC grew its holdings in CVS Health by 2.9% during the fourth quarter. Lido Advisors LLC now owns 51,433 shares of the pharmacy operator’s stock worth $3,968,000 after buying an additional 1,441 shares in the last quarter. Evolution Wealth Management Inc. raised its position in CVS Health by 1,958.2% in the 4th quarter. Evolution Wealth Management Inc. now owns 2,511 shares of the pharmacy operator’s stock valued at $199,000 after buying an additional 2,389 shares during the last quarter. Avestar Capital LLC lifted its stake in CVS Health by 12.6% during the 4th quarter. Avestar Capital LLC now owns 7,921 shares of the pharmacy operator’s stock valued at $629,000 after acquiring an additional 886 shares in the last quarter. Finally, CIBC Asset Management Inc boosted its holdings in CVS Health by 59.9% during the 4th quarter. CIBC Asset Management Inc now owns 325,001 shares of the pharmacy operator’s stock worth $25,792,000 after acquiring an additional 121,795 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to Zacks Rank #2 (Buy), signaling improved earnings optimism and adding to the case for near-term upside. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with reports noting an average recommendation of “Moderate Buy” for CVS, reinforcing investor confidence in the name. Article Title
• Positive Sentiment: Rallying health insurers such as Humana, UnitedHealth, and Cigna on hopes of softer medical cost trends is boosting sentiment across the sector and likely supporting CVS shares as well. Article Title
• Neutral Sentiment: CVS also highlighted community and behavioral-health initiatives, including senior affordable housing and expanded mental health access, which are positive for its long-term brand but unlikely to move the stock much in the short term. Article Title
• Neutral Sentiment: Broader market news, including futures weakness ahead of the jobs report, appears to be a macro backdrop rather than a CVS-specific driver. Article Title

CVS Health Stock Performance

Shares of CVS stock opened at $94.84 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market cap of $121.00 billion, a price-to-earnings ratio of 41.78, a P/E/G ratio of 0.89 and a beta of 0.62. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The firm’s 50-day simple moving average is $83.65 and its two-hundred day simple moving average is $79.91.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same quarter last year, the business posted $2.25 EPS. CVS Health’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio is currently 117.18%.

Insider Buying and Selling at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last quarter. 0.85% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CVS has been the subject of several analyst reports. JPMorgan Chase & Co. increased their target price on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Royal Bank Of Canada increased their price objective on shares of CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Barclays boosted their target price on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. Finally, Wall Street Zen raised CVS Health from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.88.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.